이 장은 원문만 있습니다. 문장별 해석은 앞 장부터 차례로 붙입니다.
2장 · Human evolution: the non-coding revolution — Comparative identification of regulatory regions
An alternative approach to identify human-specific regulatory elements is to perform functional genomics assays such as open chromatin or protein binding in multiple species and find regions with differential evidence of regulatory activity. Some of the first evidence that human-specific regulatory elements may be common came from the ENCODE project, which found that a high proportion (~50%) of the biochemically active regions identified in the human genome were not conserved across mammals. Several recent studies built on this observation and compared human epigenomic profiles (such as open chromatin, histone modifications) to those of primates and other species using either primary tissues or cell lines from various developmental stages (see below). To infer that regulatory marks are human-specific requires epigenomic profiles from chimpanzees (or bonobos), which is often impossible due to limited availability of material and ethical considerations. One potential solution is to investigate post hoc if the regions with epigenetic signatures that differ between human and rodents or monkeys intersect with HARs or harbor sequence changes that are unique to the human genome.
Cotney and colleagues performed ChIP-seq for histone H3 lysine 27 acetylation (H3K27ac, a mark of active enhancers) in human, rhesus macaque, and mouse embryonic limb at four different developmental stages from bud to digit separation, defined as orthologous based on morphology and HOXD gene expression. They found 2175 promoters and 2915 putative enhancers with significantly higher H3K27ac signal in human at one or more time points. Sixteen of these regions overlap with HARs, but most show no evidence of human accelerated substitution rates or unusual diversity patterns across modern humans.
Using a similar approach, Reilly et al. mapped active promoters and enhancers using di-methylation of histone H2 lysine 27 (H3K27me2, a promoter mark) and H3K27ac, respectively, during three stages of human, rhesus macaque, and mouse cortex development. Comparing signal for these epigenetic marks across species, the authors predicted 2855 promoters and 8996 enhancers unique to human samples (that is, with higher signal in human than other species). The majority of these regions show no evidence of human accelerated substitution rates, although 48 of them overlap HARs.
Vermunt and colleagues assayed H3K27ac in eight anatomical subdivisions of the adult brain (cerebellum, caudate nucleus, thalamic nuclei, putamen, white matter, precentral gyrus, prefrontal cortex, occipital pole) of human, chimpanzee and rhesus macaque. The authors found that 14–43% of putative enhancers and 3–10% of promoters had differential signal between human and macaque brain regions. However, only a very small fraction of these showed a similar difference between human and chimpanzee. While 284 H3K27ac regions from this study overlap with HARs, only 32 of these have significantly higher or lower H3K27ac signal in human versus chimpanzee or macaque. One particularly interesting example is 2xHAR87/HACNS548, which interacts with the promoter of the CADM1 gene and shows steadily increasing H3K27ac signal from macaque to human (Fig. 2).
Prescott et al. compared transcription factor (TF) and co-activator binding, histone modifications, and chromatin accessibility genome-wide in human and chimpanzee cranial neural crest cells (CNCCs) to pinpoint putative enhancers. They derived CNCCs from pluripotent stem cells using an in vitro protocol in which specification, migration, and maturation are recapitulated in the dish, an approach that allows unavailable chimpanzee cell types to be derived in the lab. The authors predicted ~ 1800 regulatory elements with different levels of H3K27ac in human versus chimpanzee, suggestive of differential enhancer activity. A few of these overlap HARs (three of the top 1000; Table 1). The authors found that the variance in H3K27ac signal scales proportionally with human–chimp sequence divergence. We note that sequence differences are quite low overall (three to six substitutions per 500 bp) even at regions with the biggest human–chimpanzee differences in H3K27ac binding. These results show that regions with one or two sequence changes can have different enhancer activity (measured by transgenic assays using luciferase or lacZ), which may make identifying causal sequence changes easier than in HARs with five to ten changes. Prescott et al. speculate that the enhancer activity differences they detect are due to changes in consensus transcription factor binding motifs, such as one called Coordinator. However, since enhancer assays are not highly quantitative (see below) and cannot identify upstream causes of differences in reporter gene activity, further functional experiments are important to validate the expression differences and test the hypothesis that transcription factor binding changes played a causal role in these regions.
Overall, these studies discovered many genome sequences with human-specific epigenomic signatures, which are exciting catalogs of putative regulatory elements for future studies. Since many of these regions are not deeply conserved across mammals, they complement previously identified HARs. However, most of the elements show little or no evidence of human-specific sequence change, suggesting that the causal mutations are in trans or that the catalogs contain many false positives due to the many challenges of cross-species functional genomics, such as antibody affinity, low samples sizes, and matching cell composition and developmental stage. As Prescott et al. note, regions with fewer sequence changes than a typical HAR can show enhancer activity differences, though we emphasize that it is challenging to discriminate these from the many cases where an equivalent number of sequence changes causes no activity difference. More functional validation of predicted differences in regulatory activity (for example, with reporter assays or CRISPR/Cas9 screens) will help to determine the false positive rate. Meanwhile, we should be careful when interpreting chromatin immunoprecipitation data since protein–DNA binding events cannot be directly translated into regulatory function, as has been discussed elsewhere. Another challenge is evaluating the net effect of all genetic and epigenetic changes within a locus on species-specific gene expression (reviewed in), which is particularly difficult when regulatory elements function synergistically or redundantly (Fig. 3 and below).
Transgenic approaches to study the functional impact of non-coding evolution
One approach to investigating the functional effects of human-specific non-coding sequences is to introduce them into model organisms. Despite differences in anatomy and genetic networks across species, transgenic and mutant mouse models have been useful for characterizing human-specific genes, such as ARHGAP11B and SRGAP2C, and human-specific gene variants, such as FOXP2. Predicted enhancers can also be validated and tested for effects of sequence differences using transient or stable reporter assays in mouse and zebrafish. In general, in transient transgenic enhancer assays (where the F0 generation is analyzed) enhancer function can be evaluated in only one or a small number of embryonic stages, and not in adult tissues. Although we found that many HARs appear to function during development, a substantial fraction likely cannot be characterized with this approach. Generation of stable transgenic lines (where the F1 generation is analyzed) could facilitate the analysis of many more developmental stages and adult expression. However, the low throughput of transgenic experiments has limited their utility for characterizing large catalogs of human-specific regulatory elements.
Despite these caveats, a number of human-specific non-coding sequences have been functionally characterized as enhancers in vivo with reporter assays in transgenic animal models. These include two conserved elements deleted in humans (hCONDELs), nearly 70 HARs (summarized in), including nine haDHSs, and an additional seven haDHSs that do not overlap HARs. Reporter assays in transgenic animals can also be used to test the hypothesis that human-specific mutations in non-coding elements altered their enhancer activity, and indeed several HARs and haDHSs show expression differences between constructs carrying the chimpanzee versus human sequence (Table 1). It is important to note that transient transgenics can capture gains and losses of enhancer activity in specific tissues or cell types (expression patterns), but they are not quantitative (expression level depends on number and location of random genomic integrations) and hence are unable to capture changes in activity levels. These studies aiming to analyze the function of human-specific non-coding sequences and then to study them comparatively with transgenic model organism enhancer assays are adding valuable information about the functional impact of human-specific DNA changes. Looking ahead, it will be important to supplement these with additional approaches to link enhancer activity differences to gene expression and phenotypes.
Massively parallel reporter assays (MPRAs) show promise in cell lines and may become practical in whole animals. In this technique, a library of candidate regulatory enhancer DNA sequences is cloned into a reporter construct containing a unique DNA barcode that will be transcribed if the enhancer is active. RNA-sequencing of the DNA barcodes enables quantitative measurements of enhancer activity, including effects of individual nucleotide variants. Two potential limitations of this technique are length of the candidate enhancers (<200 bp with current DNA synthesis methods) and the fact that they are usually evaluated outside of their genome context. Knock-in strategies where regulatory element variants are replaced in the analyzed locus (such as via CRISPR/Cas9 genome editing) could address this issue. Low throughput transgenic and mutant model animals can complement both techniques. A combination of methods can together enable tests of hypotheses about the effects of human-specific variants on molecular and organismal phenotypes.
이 글은 위 출처의 원문을 그 라이선스(CC BY 4.0)에 따라 옮겼습니다. 참고문헌 목록과 인용 번호, 그림 · 표 · 각주 · 수식 · 부록은 빼고 절별로 나누어 실었으며, 그 밖의 문장은 원문 그대로입니다. 원 저작자와 발행 기관은 이 화면을 만들거나 검토하지 않았고, 이곳의 해석과 낱말 풀이는 공식 번역이 아닙니다.
